SLV 341

Drug Profile

SLV 341

Alternative Names: SLV341

Latest Information Update: 05 Feb 2013

Price : $50

At a glance

  • Originator Genfit; Solvay Pharmaceuticals
  • Developer Abbott Laboratories; Genfit; Solvay Pharmaceuticals
  • Class
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 16 Mar 2010 Phase I development is ongoing in European Union
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top